Medindia LOGIN REGISTER
Medindia
Advertisement

Sleep Disorders Drug Development Pipeline Review, 2017

Friday, October 13, 2017 Drug News
Advertisement
NEW YORK, Oct. 12, 2017 /PRNewswire/ --
Advertisement

Sleep Disorders Drug Development Pipeline Review, 2017SummaryRestless legs syndrome is characterized by a distressing, irresistible need or urge to move the legs. There are a total of eight products in development for this indication, by eight companies. Key companies operating in this pipeline space include Mundipharma International and Galenica.Read the full report: https://www.reportlinker.com/p05142594Nocturia describes the excessive urination at night. There are a total of eight products in development for this indication, by six companies. Key companies operating in this pipeline space include Ferring International and Sanwa Kagaku Kenkyusho.Finally, Insomnia is a serious sleeping disorder characterized by the inability to fall or stay asleep. There are a total of 31 products in development for this indication, by 27 companies and three academic institutions. Key companies operating in this pipeline space include Johnson & Johnson, Merck and Overseas Pharmaceuticals.Across all three of these indications there is a diverse range of molecular targets due to the different pathologies of the indications. The most common targets for restless legs syndrome, nocturia and insomnia therapeutics are D2 dopamine receptor, vasopressin V2 receptor and orexin receptor, respectively.The report,"Sleep Disorders Drug Development Pipeline Review, 2017" provides an overview of the sleep disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Restless Legs Syndrome, Nocturia and Insomnia and features dormant and discontinued projects.Scope- Which companies are the most active within the pipeline for sleep disorder therapeutics?- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?- What are the most important R&D milestones and data publications to have happened in the field of sleep disorders?Reasons to buy- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administrationRead the full report: https://www.reportlinker.com/p05142594 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. https://www.reportlinker.com  __________________________ Contact Clare: [email protected]  US: (339)-368-6001 Intl: +1 339-368-6001

 

View original content:http://www.prnewswire.com/news-releases/sleep-disorders-drug-development-pipeline-review-2017-300536082.html

SOURCE Reportlinker

Sponsored Post and Backlink Submission


Latest Press Release on Drug News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close